Understand the source comparison
IGF-1 LR3 Contraindications: Research Protocol Comparison
Different research contexts apply contraindication screening with varying stringency depending on study objectives, subject populations, and regulatory oversight intensity. The table below compares exclusion criteria across three representative protocol types.
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Different research contexts apply contraindication screening with varying stringency depending on study objectives, subject populations, and regulatory oversight intensity. The table below compares exclusion criteria across three representative protocol types.
- Active Malignancy
- Species-specific tumor models acceptable
- Absolute exclusion; 5-year cancer-free interval required
- Absolute exclusion in human subjects; no restriction for isolated tissue studies
- Phase I trials require longest washout periods and most comprehensive imaging due to first-in-human risk
- Diabetic Retinopathy
- Not applicable (animal models)
- Dilated fundoscopy required; any PDR finding = exclusion
- Risk assessment based on study design; some observational protocols may include with monitoring
- Clinical trials enforce stricter exclusion than observational studies due to intervention risk
- Pediatric Subjects
- Juvenile animal models used
- Age ≥18 with radiographic bone age confirmation
- Age ≥18 universally; some protocols extend to ≥21 for long bone studies
- No legitimate research justification exists for pediatric IGF-1 LR3 administration
- Pregnancy/Lactation
- Reproductive toxicology studies conducted
- Negative beta-hCG within 7 days; dual contraception mandated
- Negative pregnancy test + contraception agreement required
- All human protocols exclude pregnancy regardless of phase or design
- Hepatic Impairment
- Liver function not limiting factor
- Child-Pugh Class B or C (score ≥7) = exclusion
- AST/ALT >3× ULN or bilirubin >2× ULN typically excludes
- Moderate-to-severe impairment excluded due to altered IGF-1 metabolism
- Renal Impairment
- Kidney function not typically screened
- eGFR <45 mL/min/1.73m² = exclusion
- eGFR <30 mL/min/1.73m² commonly used threshold
- Renal clearance affects IGF-1 LR3 elimination; severe impairment prolongs half-life unpredictably